Neurocrine Biosciences (NBIX) Net Margin (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Net Margin for 16 consecutive years, with 15.06% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Margin fell 58.0% year-over-year to 15.06%; the trailing twelve-month figure through Jun 2026 stood at 20.91% (up 703.0% YoY), and the FY2025 full-year result was 16.73%, up 224.0% from the prior year.
• Net Margin slipped to 15.06% in Q2 2026 per NBIX's latest filing, from 24.3% in the prior quarter.
• Across five years, Net Margin topped out at 28.67% in Q4 2023 and bottomed at 18.22% in Q1 2023.
• Historically, Net Margin has averaged 13.67% across 5 years, with a median of 16.54% in 2024.
• The sharpest annual moves came in 2023 and 2024: Net Margin sank 2270 bps in 2023, then surged 2664 bps in 2024.
• Over 5 years, Net Margin stood at 21.6% in 2022, then jumped by 33 bps to 28.67% in 2023, then tumbled by 43 bps to 16.43% in 2024, then increased by 16 bps to 19.08% in 2025, then declined by 21 bps to 15.06% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 15.06%, 24.3%, and 19.08% for Q2 2026, Q1 2026, and Q4 2025 respectively.